DEAL OF THE YEAR (>€500M)
This award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both the company and the wider industry. The deal could be a licensing agreement, co-development or a creative alliance or partnership that unlocks significant value.
Qualifying criteria
- Deal size must be equal to or greater than €500m
- The lead company must be a European Life Science company
- Open to private or public companies WITH pharma, commercial leaders or big tech
- Deal can be either a licensing deal, single asset acquisition or collaborative agreement involving a particular drug, project or group of drugs/projects
- A license, partnership or alliance between companies NOT M&A
- Deal / milestone to have completed in the period between 1 September 2021 and 1 September 2022
Judges will be paying particular attention to:
- Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal (upfront, milestone and total value)
- Strength of partner / partnership and deal teams
- Potential game / industry changing implications within next 12-months
- Post-deal performance
Before entering the nomination site please ensure you have:
1. Selected the most appropriate category(s) you'll be entering and check for validity of entry
2. Identified your lead applicant / internal champion who will respond to any correspondence from the ELA team
3. Pre-prepared your submission in accordance with the category criteria, spending time crafting your detailed submission.
4. A company logo and your website URL that you can upload alongside your submission
